List of Excipients in API moxifloxacin hydrochloride tablets, 400 mg
✉ Email this page to a colleague
Excipients in ANDA-approved (generic) drugs containing moxifloxacin hydrochloride tablets, 400 mg
Detailed excipient profiles for moxifloxacin hydrochloride tablets, 400 mg
Excipient focus: ANHYDROUS LACTOSE
moxifloxacin hydrochloride tablets, 400 mg drug variants containing ANHYDROUS LACTOSE
moxifloxacin hydrochloride tablets, 400 mg drug variants not containing ANHYDROUS LACTOSE
| Company | Ingredient | NDC |
|---|---|---|
| >Company | >Ingredient | >NDC |
Excipient focus: CROSCARMELLOSE SODIUM
moxifloxacin hydrochloride tablets, 400 mg drug variants containing CROSCARMELLOSE SODIUM
moxifloxacin hydrochloride tablets, 400 mg drug variants not containing CROSCARMELLOSE SODIUM
| Company | Ingredient | NDC |
|---|---|---|
| >Company | >Ingredient | >NDC |
Excipient focus: FERRIC OXIDE RED
moxifloxacin hydrochloride tablets, 400 mg drug variants containing FERRIC OXIDE RED
moxifloxacin hydrochloride tablets, 400 mg drug variants not containing FERRIC OXIDE RED
| Company | Ingredient | NDC |
|---|---|---|
| >Company | >Ingredient | >NDC |
Excipient focus: HYPROMELLOSES
moxifloxacin hydrochloride tablets, 400 mg drug variants containing HYPROMELLOSES
moxifloxacin hydrochloride tablets, 400 mg drug variants not containing HYPROMELLOSES
| Company | Ingredient | NDC |
|---|---|---|
| >Company | >Ingredient | >NDC |
Excipient focus: LACTOSE MONOHYDRATE
moxifloxacin hydrochloride tablets, 400 mg drug variants containing LACTOSE MONOHYDRATE
moxifloxacin hydrochloride tablets, 400 mg drug variants not containing LACTOSE MONOHYDRATE
| Company | Ingredient | NDC |
|---|---|---|
| >Company | >Ingredient | >NDC |
Excipient focus: MAGNESIUM STEARATE
moxifloxacin hydrochloride tablets, 400 mg drug variants containing MAGNESIUM STEARATE
moxifloxacin hydrochloride tablets, 400 mg drug variants not containing MAGNESIUM STEARATE
| Company | Ingredient | NDC |
|---|---|---|
| >Company | >Ingredient | >NDC |
Excipient focus: POLYETHYLENE GLYCOL 400
moxifloxacin hydrochloride tablets, 400 mg drug variants containing POLYETHYLENE GLYCOL 400
moxifloxacin hydrochloride tablets, 400 mg drug variants not containing POLYETHYLENE GLYCOL 400
| Company | Ingredient | NDC |
|---|---|---|
| >Company | >Ingredient | >NDC |
Excipient focus: POVIDONE K30
moxifloxacin hydrochloride tablets, 400 mg drug variants containing POVIDONE K30
moxifloxacin hydrochloride tablets, 400 mg drug variants not containing POVIDONE K30
| Company | Ingredient | NDC |
|---|---|---|
| >Company | >Ingredient | >NDC |
Excipient focus: SILICON DIOXIDE
moxifloxacin hydrochloride tablets, 400 mg drug variants containing SILICON DIOXIDE
moxifloxacin hydrochloride tablets, 400 mg drug variants not containing SILICON DIOXIDE
| Company | Ingredient | NDC |
|---|---|---|
| >Company | >Ingredient | >NDC |
Excipient focus: TITANIUM DIOXIDE
moxifloxacin hydrochloride tablets, 400 mg drug variants containing TITANIUM DIOXIDE
moxifloxacin hydrochloride tablets, 400 mg drug variants not containing TITANIUM DIOXIDE
| Company | Ingredient | NDC |
|---|---|---|
| >Company | >Ingredient | >NDC |
Make Better Decisions: Try a trial or see plans & pricing
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models. By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.
ISSN: 2162-2639
Privacy and Cookies
Terms & Conditions
Site Map
DrugPatentWatch Alternatives
LOE / Generic Entry Opportunies 2025 - 2026
NCE-1 Patent Challenge Dates 2025 - 2026
Friedman, Yali. "DrugPatentWatch" DrugPatentWatch, thinkBiotech, 2025, www.DrugPatentWatch.com.
See Primary Research Papers Citing DrugPatentWatch